Immunophotonics has announced the U.S. Food and Drug Administration (FDA) completed its safety review of the company’s Investigational New Drug (IND) application and concluded that Immunophotonics may proceed with the clinical investigation of intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors at sites within the U.S
